19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Company News

Chroma Therapeutics, GlaxoSmithKline deal

Chroma received an undisclosed milestone payment from GlaxoSmithKline under a 2009 deal under which the pharma's Centre of Excellence for External Drug Discovery received options to license exclusive, worldwide rights to four macrophage-targeted small molecule...
07:00 , Aug 30, 2010 |  BC Week In Review  |  Company News

Chroma Therapeutics, GlaxoSmithKline deal

Chroma received an undisclosed milestone payment from GlaxoSmithKline under a 2009 deal in which the pharma's Centre of Excellence for External Drug Discovery received options to license exclusive, worldwide rights to four macrophage-targeted small molecule...